David Tucker

8PUBLICATIONS
25CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)HaematologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Oct 22, 2026
CAR-HEMATOTOX score to predict risk of poor outcomes with odronextamab in heavily pretreated B-cell non-Hodgkin lymphoma.

|Apr 29, 2026
Acalabrutinib monotherapy as a first-line treatment for CLL: 3-year follow-up of the real-world EPIC study.

|Jul 18, 2022
An open-source, expert-designed decision tree application to support accurate diagnosis of myeloid malignancies.

Thomas Coats, Daniel Bean, Theodora Vatopoulou

|May 07, 2021
Treatment patterns and outcomes of unfit and elderly patients with Mantle cell lymphoma unfit for standard immunochemotherapy: A UK and Ireland analysis.

Alexandros Rampotas, Matthew R Wilson, Oliver Lomas

|May 24, 2020
The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma.

David Tucker, Nick Morley, Peter MacLean

Pageof 2

Frequent Collaborators

3 joint publications

Toby A Eyre

2 joint publications

Nimish Shah

1 joint publications

Nicolás Martínez-Calle

1 joint publications

Shankara Paneesha